Serina Therapeutics, Inc. (NYSEAM: SER)
Health Care · Biotechnology · US
$2.70
-3.57% today · -46.4% 1Y
Serina Therapeutics, Inc. (NYSEAM: SER) operates in the Biotechnology industry within the Health Care sector. The company is valued at $41.99M and employs 16 people.
Over the last twelve months the share price has lost 46.4%, trading between 1.22 and 7.92.
Tweenvest scores Serina Therapeutics, Inc. across four factors: quality 24/100. Its strongest factor is quality.
SER price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $41.99M
- Revenue (TTM)
- $0.00
- P/E
- —
- EPS
- -1.93
- Dividend yield
- —
- Beta (5Y)
- -0.00
- 52-week high
- $7.92
- 52-week low
- $1.22
- Avg volume (3M)
- —
- Shares outstanding
- 15.00M
- Employees
- 16
- Next earnings
- —
About Serina Therapeutics, Inc.
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in 2006 and is headquartered in Huntsville, Alabama.
- ISIN
- US81751A1088
- Founded
- 2006
- Listed since
- Nov 28, 2018
- Exchange
- NYSE American LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $63.06B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.